Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-arm study of subcutaneous human immunoglobulin in primary immunodeficiency
CTR20244445Phase 3Active
- Sponsor
- Sichuan Yuanda Shuyang Pharmaceutical
- Start
- May 2025
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Gamimune-N in Immunogenetic disorder, X-linked agammaglobulinemia (XLA), common variable immunodeficiency (CVID), sponsored by Sichuan Yuanda Shuyang Pharmaceutical. Started May 2025; status: active.
02
Drugs
Gamimune-N
03
Conditions
Immunogenetic disorderX-linked agammaglobulinemia (XLA)common variable immunodeficiency (CVID)
Beyond the preview
Go deeper on CTR20244445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244445.